Form 4 for AXSM Axsome Therapeutics, Inc.
Accepted 2026-08-07 19:00:04 ET · period of report 2026-08-05 · accession 0001193125-26-340688 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-07 19:00 | 2026-08-05+ | AXSM | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $4.95 | +49.7K | 11.9K | New | +$245.8K |
| DMT | 2026-08-07 19:00 | 2026-08-05+ | AXSM | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $212.19 | -49.7K | 7,229 | -87% | -$10.54M |
| DMT | 2026-08-07 19:00 | 2026-08-05+ | AXSM | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $0.00 | -49.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-05 | M | A | 45,004 | $4.95 | 52,233 | D | — | — | (F1) Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| 2 | Common | Common Stock | 2026-08-05 | S | D | 45,004 | $212.01 | 7,229 | D | — | — | (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. (F3) Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. (F4) Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $209.28 and $216.35. |
| 3 | Common | Common Stock | 2026-08-06 | M | A | 4,660 | $4.95 | 11,889 | D | — | — | (F1) Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| 4 | Common | Common Stock | 2026-08-06 | S | D | 4,660 | $213.95 | 7,229 | D | — | — | (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. (F3) Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. (F5) Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $212.41 and $216.36. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-08-05 | M | D | 45,004 | $0.00 | 4,660 | D | $212.01 · 2018-03-15 to 2027-03-15 | 45,004 Common Stock | (F1) Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-08-06 | M | D | 4,660 | $0.00 | 0 | D | $213.95 · 2018-03-15 to 2027-03-15 | 4,660 Common Stock | (F1) Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |